Single-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysis

References

• Go AS, Mozaffarian D, Roger VL, et al. Heart Disease and Stroke Statistics – 2013 Update – a report from the American Heart Association. Circulation 2013;127:143–52
   PubMed Web of Science ®Google Scholar
• Ford ES. Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States. Circulation 2011;123:1737–44
   PubMed Web of Science ®Google Scholar
• The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC): Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC guidelines for the management of arterial hypertension. J Hypertens 2013;31:1281–357
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761–88
   PubMed Web of Science ®Google Scholar
• Salahuddin A, Mushtaq M, Materson BJ. Combination therapy for hypertension 2013: an update. J Am Soc Hyper 2013;7:401–7
   PubMed Web of Science ®Google Scholar
• Dalhof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA) a multicentre randomised controlled trial. Lancet 2005;366:895–906
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417–28
   PubMed Web of Science ®Google Scholar
• Goff DC, Lloyd-Jones DM, Bennet G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2013. 2014;63:2935–59
   Google Scholar
• Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204–12
   PubMed Web of Science ®Google Scholar
• Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function – measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–83
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB, et al. American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79–108
   PubMed Web of Science ®Google Scholar
• Blackstone EH. Comparing apples and oranges. J Thorac Cardiovasc Surg 2002;123:8–15
   PubMed Web of Science ®Google Scholar
• Collier DJ, Poulter NR, Dahlöf B, et al. Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). J Hypertens 2011;29:583–91
   PubMed Web of Science ®Google Scholar
• Puig JG, Calvo C, Luurila O, et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens 2007;21:917–24
   PubMed Web of Science ®Google Scholar
• Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006;24:185–92
   PubMed Web of Science ®Google Scholar
• Cicero AF, Gerocarni B, Rosticci M, Borghi C. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens 2012;34:113–17
   PubMed Web of Science ®Google Scholar
• Canavesi M, Baldini N, Leonardi A, et al. In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol 2004;44:416–22
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, de la Figuera M, et al. High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. Int J Clin Pract 2008;62:723–8
   PubMed Web of Science ®Google Scholar
• Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005;27:73–80
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Echarri R, et al. Fixed combinations in the management of hypertension: perspectives on lercanidipine – enalapril. Vasc Health Risk Manag 2008;4:847–53
   PubMedGoogle Scholar
• Gojanovic B, Feihl F, Liaudet L, et al. 2008. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J Renin Angiotensin Aldosterone Syst 2008;9:1–9
   PubMed Web of Science ®Google Scholar
• Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Reports 2002;4:479–82
   PubMedGoogle Scholar
• Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001;14:963–8
   PubMed Web of Science ®Google Scholar